Using a new bottom-up approach for rational drug design, researchers have reengineered the powerful anticancer drug imatinib — best known by its brand name Gleevec — to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect. The modified drug just as effective against gastrointestinal cancer. The re-design strategy employed in the study is broadly applicable to reducing side effects in other drugs.